NASDAQ:TLSA Tiziana Life Sciences (TLSA) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free TLSA Stock Alerts $0.72 -0.03 (-4.46%) (As of 11:51 AM ET) Add Compare Share Share Today's Range$0.68▼$0.8950-Day Range$0.43▼$0.7552-Week Range$0.41▼$1.27Volume2.16 million shsAverage Volume125,108 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tiziana Life Sciences alerts: Email Address Tiziana Life Sciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthyDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.15) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.46 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Tiziana Life Sciences. Previous Next 3.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverTiziana Life Sciences has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Tiziana Life Sciences has recently decreased by 11.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTiziana Life Sciences does not currently pay a dividend.Dividend GrowthTiziana Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TLSA. Previous Next 2.5 News and Social Media Coverage News SentimentTiziana Life Sciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Tiziana Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added Tiziana Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tiziana Life Sciences are expected to grow in the coming year, from ($0.15) to ($0.13) per share.Price to Book Value per Share RatioTiziana Life Sciences has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Tiziana Life Sciences Stock (NASDAQ:TLSA)Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Read More TLSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLSA Stock News HeadlinesApril 23, 2024 | proactiveinvestors.comTiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access ProgramApril 23, 2024 | globenewswire.comTiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access ProgramApril 23, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. April 22, 2024 | proactiveinvestors.comTiziana Life Sciences reports additional positive results from Multiple Sclerosis programApril 22, 2024 | globenewswire.comTiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access ProgramApril 19, 2024 | proactiveinvestors.comTiziana Life Sciences' foralumab study highlighted in Neurology TodayApril 19, 2024 | globenewswire.comTiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®April 18, 2024 | proactiveinvestors.comTiziana Life Sciences says foralumab shows promise in stabilizing certain types of MSApril 23, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. April 18, 2024 | globenewswire.comTiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyApril 11, 2024 | proactiveinvestors.comTiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conferenceApril 11, 2024 | globenewswire.comTiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyMarch 20, 2024 | seekingalpha.comTLSA Tiziana Life Sciences LtdMarch 5, 2024 | finance.yahoo.comTiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s DiseaseMarch 5, 2024 | proactiveinvestors.comTiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's diseaseMarch 5, 2024 | globenewswire.comTiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's DiseaseJanuary 5, 2024 | finance.yahoo.comTiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024January 5, 2024 | finance.yahoo.comTiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated InflammationDecember 22, 2023 | proactiveinvestors.comTiziana Life Sciences starts Phase 2a trial and promises results in 2024December 19, 2023 | finance.yahoo.comTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple SclerosisDecember 4, 2023 | finance.yahoo.comTiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment WebinarNovember 30, 2023 | proactiveinvestors.comTiziana Life Sciences advances multiple sclerosis research...Tiziana Life Sciences advances multiple sclerosis research program...November 30, 2023 | finance.yahoo.comTiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple SclerosisNovember 1, 2023 | finance.yahoo.comTiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023October 20, 2023 | finance.yahoo.comTLSA: Six Month SPMS ResultsOctober 18, 2023 | proactiveinvestors.comTiziana Life Sciences: FDA signs off on home-based protocol for MS treatmentOctober 18, 2023 | finance.yahoo.comTiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis TreatmentSee More Headlines Receive TLSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TLSA CUSIPN/A CIK1723069 Webwww.tizianalifesciences.com Phone44-20-7495-2379FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book3.97Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable Beta0.82 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Gabriele Marco Antonio Cerrone M.B.A. (Age 52)Founder, Executive Chairman & Interim CEO Comp: $444kDr. Andrea BrancaleScientific FounderMr. Richard Clarkson Ph.D.Scientific FounderMr. Andrew Westwell Ph.D.Scientific FounderMs. Keeren Shah (Age 48)Chief Financial Officer Dr. Matthew W. Davis M.D.R.Ph., COO & Chief Medical OfficerDr. William A. Clementi Ph.D.Pharm.D., Chief Development OfficerDr. Napoleone Ferrara M.D. (Age 66)Member of Scientific Advisory Board More ExecutivesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors TLSA Stock Analysis - Frequently Asked Questions How have TLSA shares performed in 2024? Tiziana Life Sciences' stock was trading at $0.56 at the start of the year. Since then, TLSA shares have increased by 34.6% and is now trading at $0.7536. View the best growth stocks for 2024 here. When is Tiziana Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our TLSA earnings forecast. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Pfizer (PFE), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Moderna (MRNA), Enterprise Products Partners (EPD), Novavax (NVAX), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did Tiziana Life Sciences IPO? Tiziana Life Sciences (TLSA) raised $10 million in an IPO on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. How do I buy shares of Tiziana Life Sciences? Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TLSA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
